Gene therapy solution: The value of a CDMO as your end-to-end partner

With ongoing advances in science and technology, the cell and gene therapy pipeline has grown especially robust over the past few years. At present, Clinical Trials.gov shows more than 4,500 active gene therapy trials globally. In the United States, McKinsey experts expect to see 10 to 20 cell and gene therapy approvals per year over the next five years. 

This article discusses the important factors to consider when selecting an outsourcing partner for your advanced therapies. 

Download Article

 

Lyophilized products are on the rise: Here's what you need to know

There has been a steady increase in demand for lyophilized products in recent years. Due in large part to biologic drug...

READ MORE

BioPharm Intl Regulatory Sourcebook: GMPs Guide COVID-19 Vaccine Manufacturing

Excerpt taken from BioPharm International October 2020 Regulatory Sourcebook article titled: GMPs Guide COVID-19 Vaccine...

READ MORE

Editorial: Good Manufacturing Practices: Challenges with Compliance

Dino Muzzin, Senior Vice President, Manufacturing Operations at Emergent, recently contributed to an article in BioPharm...

READ MORE